So Much STI Data: Information to help you stay current and informed - RECORDED WEBINAR

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour for completing the activity (ACPE UAN 0009-0000-25-030-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

1.) A 19-year-old female is at the clinic. She had recent unprotected sexual intercourse with her partner. She has not had any previous STI screenings. Which STIs are indicated for screening at this time?
a. HIV, gonorrhea, and chlamydia
b. Gonorrhea, chlamydia, and syphilis
c. Chlamydia, syphilis, and HPV

2.) Which of the following STIs have shown a continued increase in incidence based on 2023 data?
a. Congenital syphilis
b. Gonorrhea in the population
c. Chlamydia cases in men

3.) After completing gonorrhea treatment, when should a clinician re-screen the patient?
a. 1 month after completing treatment
b. 3 months after completing treatment
c. 1 year after completing treatment

4.) What is the guideline-based treatment recommendation for a 200 lb male patient with a confirmed gonorrhea and chlamydia co-infection?
a. Ceftriaxone 500 mg IM x 1 and azithromycin 1000 mg PO x 1
b. Ceftriaxone 250 mg IM x 1 and doxycycline 100 mg PO BID x 7 days
c. Ceftriaxone 500 mg IM x 1 and doxycycline 100 mg PO BID x 7 days

5.) Which population should receive seven days of treatment with metronidazole for trichomoniasis?
a. Young males 15 – 24 years old
b. Males 25 – 45 years old
c. Females of any age

6.) A pregnant patient is positive for primary syphilis. What is the guideline recommended treatment for her?
a. 2.4 million units benzathine penicillin G IM x 1
b. 2.4 million units benzathine penicillin G IM x 3 weekly doses
c. 100 mg PO doxycycline 2 time daily doses for 28 days
7.) Which of the following is a newly approved type of product that will increase patient access?
a. OTC bacterial Pre-Exposure Prophylaxis
b. OTC home screening tests for STIs
c. OTC HIV Post Exposure Prophylaxis

8.) What should pharmacists warn healthcare providers about regarding possible alternatives during a shortage of Bicillin LA for syphilis?
a. Impact of HIV cases
b. Adverse effects from the frequent use of the medication
c. Antimicrobial resistance

9.) You are working with emergency department physicians to manage a shortage of ceftriaxone. One concern is the treatment of gonorrhea. Which of the following would be a stewardship principle applied to this STI management choice?
a. Use the most recent antibiotic approved for the indication
b. Use alternative based on narrowest effect spectrum and incorporating local resistance data, if known
c. Choose an alternative that will also cover other STIs just in case

So Much STI Data: Information to help you stay current and informed – RECORDED WEBINAR

Learning Objectives

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts

Post Test Pharmacist